Aktualne próby kliniczne, w których nasz Ośrodek bierze aktywny udział:

• PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: Dowiedz się więcej
• SELINA:Prevention of Female Cancers by Optimization of Selenium Levels in the Organism: Dowiedz się więcej
• SERENA4: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: Dowiedz się więcej
• ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients: Dowiedz się więcej
• LUCY: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients:  Dowiedz się więcej
• OLYMPIA: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Dowiedz się więcej
• VIOLETTE: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Dowiedz się więcej
• SOLO-2: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Dowiedz się więcej
• SOLO-1: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy Dowiedz się więcej

•  MONO-OLA1: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy: Dowiedz się więcej
• OREO: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Dowiedz się więcej